Hypothalamic POMC neurons regulate intestinal glucose absorption via a gut–brain circuit Authors: Hyo Sun Lim, Se Hee Min, Hyo Jin Kim, Chae Beom Park, Seong Jun Kim, Mun Gyeom Kim, Ji Su Kim, Jun Young Byun, Se Eun Park, Myeong Ju Kim, So Yeon Jeong, Jin A. An, Seokbeom Seo, Joomi Park, Yeji Kim, Ji Ye Kim, Sang Ju Lee, Seog-Young Kim, Xin Yi Yeo, Edra London, Jong-Woo Sohn, Gil Myoung Kang, Sangyong Jung, Min-Seon Kim Published: 2026 ABSTRACT Hypothalamic proopiomelanocortin (POMC)-producing neurons are essential for maintaining energy balance and glucose homeostasis. We show that cAMP-dependent protein kinase A (PKA) signaling in these neurons is activated postprandially and upon the administration of glucagon-like peptide-1-based antiobesity/antidiabetic agents. To investigate the metabolic regulatory role of PKA signaling in hypothalamic POMC neurons, we generated mice with POMC-specific constitutive PKA activation by depleting the PKA regulatory subunit Prkar1a. These mice developed obesity due to PKA activation in pituitary corticotrophs and hypercortisolism. Despite increased insulin resistance, these animals exhibited a marked improvement in glucose tolerance, attributable to reduced intestinal glucose absorption and increased fecal glucose excretion. Mechanistically, PKA activation in hypothalamic POMC neurons stimulated upper gut innervating-vagal motor neurons, leading to a suppression of sodium/glucose cotransporter-1 (SGLT1)-dependent intestinal glucose absorption. Our findings indicate that the POMC PKA signaling−vagal−gut SGLT1 axis may be a potential target for antidiabetic treatment in individuals with insulin resistance. Introduction Diabetes is a chronic metabolic disorder that has reached epidemic proportions worldwide, thus presenting a major global public health challenge1. The pathophysiology of diabetes mellitus is complex and involves multiple mechanisms that disrupt glucose homeostasis. The concept of the “ominous octet” outlines key pathophysiological abnormalities that contribute to elevated blood glucose levels and the progression of diabetes2. These abnormalities include insulin resistance in peripheral tissues, reduced insulin secretion and increased glucagon secretion from the pancreas, increased hepatic glucose production, impaired incretin hormone action, enhanced lipolysis in adipose tissues, increased renal glucose reabsorption, and altered neurotransmitter signaling in the brain2. Despite significant advances in diabetic medications offering various treatment options, unmet clinical needs remain3. Therefore, novel therapeutic strategies targeting previously underexplored mechanisms of diabetes are still required. The regulation of glucose homeostasis involves a complex network of metabolic organs under the precise control of hypothalamic neurons4. Proopiomelanocortin (POMC)-producing neurons in the hypothalamic arcuate nucleus (ARC) are particularly responsive to fluctuations in glucose levels and metabolic hormones5–7. These neurons regulate a range of physiological processes critical to energy and glucose homeostasis, including food intake, adipose tissue thermogenesis, pancreatic insulin secretion, hepatic glucose production, and renal glucose reabsorption8–12. Impaired glucose or metabolic hormonal sensing and signaling in these neurons may contribute to the development of diabetes and broader metabolic dysfunction. The cAMP-dependent protein kinase A (PKA) serves as a key signaling mediator for several gastrointestinal hormones, including glucagon-like peptide-1 (GLP-1), GLP-2, glucose-dependent insulinotropic polypeptide (GIP), glucagon, cholecystokinin, and others13–16. ARC POMC neurons express receptors for gut hormones, such as GLP-1, GLP-2, and GIP, which activate the cAMP–PKA signaling pathway17–19. In this present study, we investigated the role of PKA signaling in hypothalamic POMC neurons in the regulation of systemic metabolism by generating a mouse model of POMC-specific PKA activation. Results Semaglutide, tirzepatide, and food intake activate PKA signaling in hypothalamic POMC neurons We first examined whether the PKA signaling in ARC POMC neurons would be affected by the administration of GLP-1-based agents or by feeding. PKA signaling activation was assessed by measuring the PKA-dependent phosphorylation and nuclear translocation of the cAMP response element-binding (CREB) in mouse POMC neurons. Semaglutide and tirzepatide were administered intraperitoneally to overnight-fasted C57BL/6J mice, and brains were collected 30 min after injections. Both semaglutide and tirzepatide significantly increased the percentages of POMC neurons exhibiting the nuclear expression of phosphorylated CREB (pCREB) compared to saline injections (Fig. 1a). Similarly, the percentage of POMC neurons with nuclear pCREB expression was elevated in the postprandial state (Fig. 1b), when GLP-1 and GIP are secreted from the gut20. These findings suggest that POMC PKA signaling may serve as a downstream mediator of postprandial metabolic adaptation and the actions of GLP-1 and GIP receptor agonists.Fig. 1Activation of PKA signaling in POMC neurons by GLP-1-based antiobesity/antidiabetic agents and food intake.pCREB and POMC (β-endorphin) double immunostaining demonstrating that an intraperitoneal injection of semaglutide (10 nmol/kg) and tirzepatide (9 nmol/kg) (a), as well as food intake (b), promotes nuclear translocation of pCREB, an indicator of PKA activation, in POMC neurons of the hypothalamic arcuate nucleus (ARC) (n = 5 male mice per group). Scale bars, 20 μm. Data are the mean ± s.e.m. Statistical analyses used were one-way ANOVA with Tukey’s test (a) and two-tailed unpaired Student’s t test (b). Source data are provided as a Source data file. Activation of PKA signaling in POMC neurons by GLP-1-based antiobesity/antidiabetic agents and food intake. pCREB and POMC (β-endorphin) double immunostaining demonstrating that an intraperitoneal injection of semaglutide (10 nmol/kg) and tirzepatide (9 nmol/kg) (a), as well as food intake (b), promotes nuclear translocation of pCREB, an indicator of PKA activation, in POMC neurons of the hypothalamic arcuate nucleus (ARC) (n = 5 male mice per group). Scale bars, 20 μm. Data are the mean ± s.e.m. Statistical analyses used were one-way ANOVA with Tukey’s test (a) and two-tailed unpaired Student’s t test (b). Source data are provided as a Source data file. POMC-specific PKA activation leads to obesity and hypercortisolism To activate PKA signaling in POMC neurons, we generated a mouse model with a targeted deletion of the Prkar1a gene, which encodes the inhibitory regulatory subunit type 1α (RIα) of PKA, in these neurons using the Cre-loxP system (Fig. 2a). To confirm effective depletion of Prkar1a in ARC POMC neurons, we conducted fluorescence in situ hybridization (FISH) analysis followed by β-endorphin immunostaining. The Prkar1a expression levels were found to be significantly reduced in the ARC POMC neurons of Pomc-Cre;Prkar1afl/fl (hereafter referred to as Prkar1aPomcKO) mice compared to the Prkar1afl/fl wild-type (Prkar1aWT) littermates, confirming successful gene depletion (Fig. 2b). POMC is also expressed in pituitary corticotrophs and some neurons in the nucleus of the solitary tract (NTS)21,22. Consistent with the inhibitory regulatory role of RIα, Prkar1aPomcKO mice exhibited increased PKA activity in the mediobasal hypothalamus (MBH), which includes the ARC, as well as in the pituitary glands, with a trend toward increased activity in the dorsal vagal complex (DVC), which contains the NTS (Fig. 2c). In contrast, despite POMC expression in enteroendocrine L-cells23, PKA activity in the terminal ileum was comparable between Prkar1aWT and Prkar1aPomcKO mice (Fig. 2c).Fig. 2POMC-specific PKA activation leads to obesity and hypercortisolism.a, b Generation of a mouse model with POMC-specific constitutive PKA activation by deleting Prkar1a, which encodes the PKA inhibitory regulatory subunit R1α (Prkar1aPomcKO mice). Successful deletion of Prkar1a in ARC POMC neurons was confirmed by Prkar1a FISH and POMC (β-endorphin) immunostaining (n = 5 male mice per group). Scale bar, 50 μm. AC, adenylate cyclase; 3V, third ventricle. The mouse silhouettes in (a) were created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. c Measurement of PKA activity in the mediobasal hypothalamus (MBH), dorsal vagal complex (DVC), pituitary gland, and terminal ileum, regions that contain POMC cells (n = 6 males for MBH, DVC, and pituitary; n = 3 for terminal ileum per group). d Gross morphology of male Prkar1aPomcKO mice at the indicated ages. Body weights (e, n = 8), fat mass, and lean mass (f, g) in Prkar1aPomcKO males and females compared with sex- and age-matched controls (n = 4 for WT males, WT females, and PomcKO males; n = 3 for PomcKO females). h Increased plasma corticosterone levels in Prkar1aPomcKO male mice (n = 5 per group). i Representative images of adrenal cortical hypertrophy in Prkar1aPomcKO male mice. Scale bar, 50 μm. C cortex, M medulla. Representative images from three independent experiments are shown. Bilateral adrenalectomy reverses hypercortisolism (j), alopecia (k), increased body weights and fat mass (l, m) in Prkar1aPomcKO male mice (n = 4 for WT; n = 5 for PomcKO and KO + ADX). Data are the mean ± s.e.m.; statistical analyses used were two-tailed unpaired Student’s t test (b, c, f–h), one-way ANOVA with Tukey’s test (j, l, m), and repeated measures two-way ANOVA (e). Source data are provided as a Source data file. POMC-specific PKA activation leads to obesity and hypercortisolism. a, b Generation of a mouse model with POMC-specific constitutive PKA activation by deleting Prkar1a, which encodes the PKA inhibitory regulatory subunit R1α (Prkar1aPomcKO mice). Successful deletion of Prkar1a in ARC POMC neurons was confirmed by Prkar1a FISH and POMC (β-endorphin) immunostaining (n = 5 male mice per group). Scale bar, 50 μm. AC, adenylate cyclase; 3V, third ventricle. The mouse silhouettes in (a) were created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. c Measurement of PKA activity in the mediobasal hypothalamus (MBH), dorsal vagal complex (DVC), pituitary gland, and terminal ileum, regions that contain POMC cells (n = 6 males for MBH, DVC, and pituitary; n = 3 for terminal ileum per group). d Gross morphology of male Prkar1aPomcKO mice at the indicated ages. Body weights (e, n = 8), fat mass, and lean mass (f, g) in Prkar1aPomcKO males and females compared with sex- and age-matched controls (n = 4 for WT males, WT females, and PomcKO males; n = 3 for PomcKO females). h Increased plasma corticosterone levels in Prkar1aPomcKO male mice (n = 5 per group). i Representative images of adrenal cortical hypertrophy in Prkar1aPomcKO male mice. Scale bar, 50 μm. C cortex, M medulla. Representative images from three independent experiments are shown. Bilateral adrenalectomy reverses hypercortisolism (j), alopecia (k), increased body weights and fat mass (l, m) in Prkar1aPomcKO male mice (n = 4 for WT; n = 5 for PomcKO and KO + ADX). Data are the mean ± s.e.m.; statistical analyses used were two-tailed unpaired Student’s t test (b, c, f–h), one-way ANOVA with Tukey’s test (j, l, m), and repeated measures two-way ANOVA (e). Source data are provided as a Source data file. Gross morphology analysis revealed that Prkar1aPomcKO male mice were smaller at 7 weeks old and appeared shorter and fatter by 15 weeks, compared to age- and sex-matched controls (Fig. 2d). Body weight monitoring showed that male Prkar1aPomcKO mice had lower body weights than control mice up to 15 weeks of age, after which their body weights became comparable to those of wild-type animals until sacrifice (Fig. 2e). In contrast, female Prkar1aPomcKO mice maintained a similar body weight to the controls up to 15 weeks of age, after which they exhibited accelerated weight gain (Fig. 2e). Body composition analysis indicated that both male and female Prkar1aPomcKO mice had a higher fat mass and lower lean mass than their wild-type counterparts at both 12 and 28 weeks of age (Fig. 2f, g). To circumvent possible developmental defects, we induced adult-inducible Prkar1a depletion by administering tamoxifen into Pomc-CreERT2;Prkar1afl/fl mice at 7 weeks of age. Pomc-CreERT2;Prkar1afl/fl mice exhibited a lower body weight until 13–15 weeks of age, followed by a subsequent increase (Supplementary Fig. 1a, b). At 20 weeks of age, these mice exhibited increased fat mass without changes in their lean mass (Supplementary Fig. 1c, d). Food intake was assessed to determine whether the body weight differences observed in the Prkar1a-deficient animals were attributable to altered feeding behavior. Male Prkar1aPomcKO mice showed no difference in cumulative food intake, whereas female Prkar1aPomcKO mice exhibited increased food intake (Supplementary Fig. 2a, b). Adult-inducible Prkar1aPomcKO mice showed no difference in food intake (Supplementary Fig. 2c, d). These findings indicate that the altered body weight and fat accumulation observed in Prkar1aPomcKO mice are unlikely to be a result of hyperphagia. Notably, the Prkar1aPomcKO mice exhibited alopecia (Fig. 2d), a phenotype previously observed in corticotropin-releasing hormone (CRH) transgenic mice with corticosterone excess24. It is well established that PKA activation in POMC-expressing corticotrophs stimulates adrenocorticotropic hormone (ACTH) secretion, leading to increased corticosterone production in the adrenal glands25. We thus speculated that Prkar1aPomcKO mice may display a phenotype indicative of corticosterone excess, reminiscent of Cushing’s syndrome in humans26. Supporting this hypothesis, Prkar1aPomcKO mice demonstrated increased plasma corticosterone levels and adrenal cortical hypertrophy (Fig. 2h, i). Histological analysis of Prkar1aPomcKO mice revealed marked lipid accumulation across multiple adipose depots and in the liver, skeletal muscle, bone marrow, and subcutaneous tissue, accompanied by atrophy of the skin, skin appendages, ovaries, uterus, and spleen (Supplementary Fig. 3a, b). Consistently, Pomc-CreERT2;Prkar1afl/fl mice exhibited increased adiposity across multiple fat depots (Supplementary Fig. 3c). Importantly, bilateral adrenalectomy normalized plasma cortisol levels and largely reversed weight gain, adiposity, and alopecia in Prkar1aPomcKO mice (Fig. 2j-m), supporting a glucocorticoid-dependent mechanism. POMC PKA activation enhances glucose tolerance through gut-related mechanisms We next examined glucose metabolism in the Prkar1aPomcKO mice. During an insulin tolerance test (ITT), Prkar1aPomcKO mice exhibited a smaller drop in blood glucose levels compared to their wild-type counterparts (Fig. 3a). The fasting blood insulin levels and the HOMA-IR index, an indicator of insulin resistance, were significantly elevated in these mice (Fig. 3b, c). Consistently, pancreas insulin staining showed increased β-cell mass and islet hypertrophy in the Prkar1aPomcKO mice (Supplementary Fig. 3d). These metabolic alterations are likely secondary to ectopic lipid accumulation in skeletal muscle and liver, together with excess lipid storage in adipose tissue, in the context of obesity and hypercortisolism (Supplementary Fig. 3a–c), all of which are well-established contributors to insulin resistance27.Fig. 3Mice with POMC-specific PKA activation exhibit insulin resistance, but display improved glucose tolerance via gut-related mechanisms.a Insulin tolerance test (ITT) results for Prkar1aPomcKO male mice (n = 7 per group). AOC, area over the curve of the plasma glucose levels during the ITT. b Plasma insulin levels measured in overnight-fasted conditions (n = 6 male mice per group). c Homeostatic model assessment of insulin resistance (HOMA-IR) index, an indicator of insulin resistance (n = 6 male mice per group). d Oral glucose tolerance test (OGTT) in 8-week-old Prkar1aPomcKO males and their sex-matched littermates (n = 6 male mice per group). AUC, area under the curve. e OGTT in Prkar1aPomcKO males with either a sham operation (OP) or bilateral adrenalectomy (ADX) (n = 5 male mice per group). Repeated two-way ANOVA; P = 2.1 × 10−16 (time) with Tukey’s post hoc test. Changes in 24 h-urine glucose excretion (f, n = 5 for WT, and n = 6 for PomcKO) and renal expression of glucose reabsorption-related genes (g, n = 8 for WT, and n = 7 for PomcKO) in Prkar1aPomcKO male mice. h Twenty-four h-fecal glucose excretion in freely-fed conditions (n = 8 male mice per group). i Intravenous glucose tolerance test (IVGTT) in 15-week-old Prkar1aPomcKO male mice and wild controls (n = 9 per group). j Plasma glucagon-like peptide 1 (GLP-1) levels during OGTT (n = 5 male mice per group). k Effects of the prior administration of the sodium/glucose cotransporter (SGLT)-1/2 inhibitor phlorizin (10 μg/g) on glucose tolerance during an OGTT (n = 6 male mice per group). Repeated two-way ANOVA; P = 1.4 × 10−23 (time) with Tukey’s post hoc test. l Changes in SGLT1 protein expression in the upper jejunum of 14 week-old Prkar1aPomcKO males and females (n = 5 for WT males, WT females, and PomcKO females; n = 6 for PomcKO males). Scale bar, 100 μm. Blood (m) and fecal (n) Me-4FDG levels following the oral gavage of 18F-Me-4FDG (n = 5 male mice per group). Data are the mean ± s.e.m. Statistical analyses used were two-tailed unpaired Student’s t test (a–d, f–j, l–n), repeated measures two-way ANOVA (a, d, m-graph), and one-way ANOVA with Tukey’s test (e, k). ns, not significant (P > 0.05). Source data are provided as a Source data file. Mice with POMC-specific PKA activation exhibit insulin resistance, but display improved glucose tolerance via gut-related mechanisms. a Insulin tolerance test (ITT) results for Prkar1aPomcKO male mice (n = 7 per group). AOC, area over the curve of the plasma glucose levels during the ITT. b Plasma insulin levels measured in overnight-fasted conditions (n = 6 male mice per group). c Homeostatic model assessment of insulin resistance (HOMA-IR) index, an indicator of insulin resistance (n = 6 male mice per group). d Oral glucose tolerance test (OGTT) in 8-week-old Prkar1aPomcKO males and their sex-matched littermates (n = 6 male mice per group). AUC, area under the curve. e OGTT in Prkar1aPomcKO males with either a sham operation (OP) or bilateral adrenalectomy (ADX) (n = 5 male mice per group). Repeated two-way ANOVA; P = 2.1 × 10−16 (time) with Tukey’s post hoc test. Changes in 24 h-urine glucose excretion (f, n = 5 for WT, and n = 6 for PomcKO) and renal expression of glucose reabsorption-related genes (g, n = 8 for WT, and n = 7 for PomcKO) in Prkar1aPomcKO male mice. h Twenty-four h-fecal glucose excretion in freely-fed conditions (n = 8 male mice per group). i Intravenous glucose tolerance test (IVGTT) in 15-week-old Prkar1aPomcKO male mice and wild controls (n = 9 per group). j Plasma glucagon-like peptide 1 (GLP-1) levels during OGTT (n = 5 male mice per group). k Effects of the prior administration of the sodium/glucose cotransporter (SGLT)-1/2 inhibitor phlorizin (10 μg/g) on glucose tolerance during an OGTT (n = 6 male mice per group). Repeated two-way ANOVA; P = 1.4 × 10−23 (time) with Tukey’s post hoc test. l Changes in SGLT1 protein expression in the upper jejunum of 14 week-old Prkar1aPomcKO males and females (n = 5 for WT males, WT females, and PomcKO females; n = 6 for PomcKO males). Scale bar, 100 μm. Blood (m) and fecal (n) Me-4FDG levels following the oral gavage of 18F-Me-4FDG (n = 5 male mice per group). Data are the mean ± s.e.m. Statistical analyses used were two-tailed unpaired Student’s t test (a–d, f–j, l–n), repeated measures two-way ANOVA (a, d, m-graph), and one-way ANOVA with Tukey’s test (e, k). ns, not significant (P > 0.05). Source data are provided as a Source data file. Remarkably, and despite insulin resistance, Prkar1aPomcKO male and female mice demonstrated a significant improvement in glucose tolerance in an oral glucose tolerance test (OGTT) (Fig. 3d and Supplementary Fig. 4a). As expected, bilateral adrenalectomy did not reverse the improved glucose tolerance in Prkar1aPomcKO mice; instead, it further enhanced it (Fig. 3e). These data strongly suggested the involvement of underlying mechanisms that are independent of both insulin sensitivity and adrenal hormones. Previous studies have shown that ARC Pomc-deficient mice exhibit improved glucose tolerance due to increased renal glucose excretion8,28. These studies also demonstrated that ARC-derived Pomc products facilitate renal glucose reabsorption by promoting sympathetic nervous system–mediated upregulation of renal glucose transporter 2 (GLUT2) expression8,28. Based on these findings, we examined urinary glucose excretion in Prkar1aPomcKO mice and found reduced glycosuria, accompanied by increased renal expression of sodium-glucose cotransporter-2 (Sglt2), Sglt1, and Glut2, which are key mediators of renal glucose reabsorption29 (Fig. 3f, g). These results suggest that renal glucose reabsorption is enhanced in Prkar1aPomcKO mice; however, this alteration does not appear to account for their improved glucose metabolism. We next investigated fecal glucose excretion. Notably, the 24-h collected feces from freely-fed Prkar1aPomcKO mice contained significantly higher amounts of glucose compared to both wild-type controls in males and females (Fig. 3h and Supplementary Fig. 4b). This data led us to speculate that Prkar1aPomcKO mice may improve glucose tolerance through increased intestinal glucose excretion. To confirm this hypothesis, we conducted an intravenous glucose tolerance test (IVGTT). Prkar1aPomcKO mice exhibited indistinguishable glucose tolerance from Prkar1aWT mice when glucose was directly administered into the bloodstream (Fig. 3i). These data strongly suggested that a gut-related mechanism may underlie the enhanced glucose tolerance in Prkar1aPomcKO mice. There was no difference in blood concentrations of gut-released incretin hormone GLP-1 between Prkar1aPomcKO and Prkar1aWT mice before and after oral gavage of glucose (Fig. 3j). Thus, incretin-unrelated gut mechanisms may account for the observed improvement in glucose tolerance in Prkar1aPomcKO mice. To investigate the mechanisms underlying altered gut glucose absorption, we examined the role of intestinal SGLT1, the primary transporter responsible for glucose uptake across the intestinal brush border30. In Prkar1aWT mice, inhibition of intestinal glucose absorption using the SGLT1/2 inhibitor phlorizin attenuated the rise in blood glucose levels during an OGTT (Fig. 3k). This effect was absent in Prkar1aPomcKO mice (Fig. 3k), suggesting reduced intestinal SGLT1 activity. Consistently, SGLT1 immunohistochemistry and immunoblotting demonstrated decreased SGLT1 expression in the upper jejunum of both male and female Prkar1aPomcKO mice compared with sex-matched Prkar1aWT controls (Fig. 3l and Supplementary Fig. 4c). A similar reduction in intestinal SGLT1 expression was observed in inducible Prkar1aPomcKO mice (Supplementary Fig. 4d). To directly assess SGLT1-mediated intestinal glucose absorption, we used the SGLT-specific glucose transport tracer methyl-4-deoxy-4-[(18F)fluoro-α-D-glucopyranoside] (Me-4FDG)31,32. Me-4FDG was administered via oral gavage following an overnight fast, and its absorption and excretion were evaluated by measuring fluorescence intensity in plasma and feces. Prkar1aPomcKO mice showed a reduced area under the curve (AUC) for plasma Me-4FDG over 120 min, along with increased fecal excretion (Fig. 3m, n). Given the minimal expression of SGLT2 in the intestine33, these findings indicate a reduction in SGLT1-mediated glucose absorption in Prkar1aPomcKO mice. Parasympathetic pathway mediates POMC neuronal regulation of intestinal glucose disposal We further investigated the mechanism underlying the enhanced intestinal glucose disposal observed in Prkar1aPomcKO mice. As ARC POMC neurons regulate peripheral glucose metabolism through the autonomic nervous system34, we hypothesized that the sympathetic or parasympathetic nervous system may mediate the glucose phenotype caused by POMC PKA activation. To test this, we administered autonomic blockers prior to an OGTT to determine which intervention reversed the improved glucose tolerance in Prkar1aPomcKO mice. First, an injection of the α-adrenergic blocker phentolamine did not reverse the enhanced glucose tolerance Prkar1aPomcKO mice but instead significantly blunted the rise in plasma glucose during the OGTT in both genotypes (Fig. 4a), suggesting that α-adrenergic signaling impairs glucose tolerance in both groups. Second, the β-adrenergic blocker propranolol modestly elevated glucose levels at later time points in both groups but did not abolish the improved glucose tolerance in Prkar1aPomcKO mice (Fig. 4b). Third, while administration of the parasympathetic blocker atropine did reverse the improved glucose tolerance in Prkar1aPomcKO mice, it had no clear effect in Prkar1aWT controls (Fig. 4c). To confirm that the anticholinergic effects of atropine were mediated through peripheral parasympathetic pathways, we administered the peripherally restricted atropine analog atropine methyl nitrate (ATMN) prior to the OGTT. Similar to atropine, ATMN had minimal effects on glucose tolerance in Prkar1aWT mice but markedly reversed the enhanced glucose tolerance observed in Prkar1aPomcKO mice (Supplementary Fig. 5a). These results suggested that enhanced peripheral parasympathetic activity is a key mediator of the improved glucose tolerance observed in Prkar1aPomcKO mice.Fig. 4Parasympathetic pathway mediates POMC PKA signaling-induced inhibition of intestinal glucose absorption.Effects of pretreatment with the α-adrenergic blocker phentolamine (a, n = 5 for WT, WT + PHEN, and KO; n = 3 for KO + PHEN) and the β-adrenergic blocker propranolol (b, n = 4 for WT; n = 5 for WT + PRO, KO, and KO + PRO) on glucose tolerance in Prkar1aPomcKO and Prkar1aWT male mice. Repeated two-way ANOVA; p = 1.1 × 10−16 (time) with Tukey’s post hoc test. Effects of pretreatment with the parasympathetic inhibitor atropine on plasma glucose (c, n = 3 for WT; n = 4 for KO; n = 5 for WT + AT, and KO + AT), fecal glucose excretion (d, n = 5 for WT, WT + AT, and KO; n = 7 for KO + AT), plasma Me-4FDG levels (e, n = 7 for WT and KO; n = 6 for WT + AT, and KO + AT), and fecal Me-4FDG excretion (f, n = 5 for WT, and WT + AT; n = 4 for KO, and KO + AT) following oral glucose gavage in Prkar1aPomcKO male mice. g Effects of a parasympathetic blockade with atropine on jejunal SGLT1 expression in Prkar1aPomcKO male mice (n = 5 per group). Scale bar, 100 μm. h–l Effects of acetylcholine-induced parasympathetic activation on glucose tolerance, fecal glucose excretion, intestinal Me-4FDG uptake and excretion, and jejunal SGLT1 expression in C57 male mice (n = 6 per group). Scale bar, 100 μm. Data are the mean ± s.e.m. Statistical analyses used were one-way ANOVA with Tukey’s test (a–g), repeated measures two-way ANOVA (h, j-graph), and two-tailed unpaired Student’s t test (h–l). ns, not significant (P > 0.05). Source data are provided as a Source data file. Parasympathetic pathway mediates POMC PKA signaling-induced inhibition of intestinal glucose absorption. Effects of pretreatment with the α-adrenergic blocker phentolamine (a, n = 5 for WT, WT + PHEN, and KO; n = 3 for KO + PHEN) and the β-adrenergic blocker propranolol (b, n = 4 for WT; n = 5 for WT + PRO, KO, and KO + PRO) on glucose tolerance in Prkar1aPomcKO and Prkar1aWT male mice. Repeated two-way ANOVA; p = 1.1 × 10−16 (time) with Tukey’s post hoc test. Effects of pretreatment with the parasympathetic inhibitor atropine on plasma glucose (c, n = 3 for WT; n = 4 for KO; n = 5 for WT + AT, and KO + AT), fecal glucose excretion (d, n = 5 for WT, WT + AT, and KO; n = 7 for KO + AT), plasma Me-4FDG levels (e, n = 7 for WT and KO; n = 6 for WT + AT, and KO + AT), and fecal Me-4FDG excretion (f, n = 5 for WT, and WT + AT; n = 4 for KO, and KO + AT) following oral glucose gavage in Prkar1aPomcKO male mice. g Effects of a parasympathetic blockade with atropine on jejunal SGLT1 expression in Prkar1aPomcKO male mice (n = 5 per group). Scale bar, 100 μm. h–l Effects of acetylcholine-induced parasympathetic activation on glucose tolerance, fecal glucose excretion, intestinal Me-4FDG uptake and excretion, and jejunal SGLT1 expression in C57 male mice (n = 6 per group). Scale bar, 100 μm. Data are the mean ± s.e.m. Statistical analyses used were one-way ANOVA with Tukey’s test (a–g), repeated measures two-way ANOVA (h, j-graph), and two-tailed unpaired Student’s t test (h–l). ns, not significant (P > 0.05). Source data are provided as a Source data file. We further investigated whether parasympathetic inhibition with atropine could reverse the increased intestinal glucose disposal in these mice. The prior administration of atropine or ATMN significantly inhibited increased fecal glucose excretion (Fig. 4d and Supplementary Fig. 5b). Moreover, atropine pretreatment reversed the reduced intestinal absorption of Me-4FDG and the increased fecal excretion of Me-4FDG in Prkar1aPomcKO mice with no effects in Prkar1aWT mice (Fig. 4e, f). Consistently, both atropine and ATMN reversed the reduced jejunal SGLT1 expression in Prkar1aPomcKO mice (Fig. 4g and Supplementary Fig. 5c). Collectively, these findings suggested that parasympathetic overactivation in Prkar1aPomcKO mice may contribute to decreased intestinal glucose absorption. We next conducted the inverse analysis by testing the effects of parasympathetic activation on intestinal glucose absorption and disposal. Prior administration of acetylcholine, a chief neurotransmitter of the parasympathetic nervous system, reduced blood glucose elevations at 15 and 30 min during OGTT and increased fecal glucose excretion without altering the plasma insulin levels (Fig. 4h, i, and Supplementary Fig. 6). Similar to Prkar1aPomcKO mice, an acetylcholine injection reduced intestinal Me-4FDG absorption and increased fecal Me-4FDG excretion in freely-fed normal mice (Fig. 4j, k). Additionally, acetylcholine injection suppressed SGLT1 expression in the upper gut (Fig. 4l). These findings further supported the hypothesis that parasympathetic activation inhibits intestinal glucose absorption and promotes intestinal glucose disposal. ARC POMC neuron-specific Prkar1a depletion promotes intestinal glucose disposal Because gene modulation using Pomc-Cre mice can affect POMC neurons in both the ARC and the NTS, we sought to isolate the effects of PKA activation specifically in ARC POMC neurons on gut glucose disposal. To achieve this, we bilaterally injected a Cre-dependent adeno-associated virus (AAV) expressing eGFP and a small hairpin RNA targeting Prkar1a (shPrkar1a-AAV) into the ARC of Pomc-Cre mice. Control mice received the same AAV expressing a non-targeting shRNA, and eGFP (shControl-AAV) (Fig. 5a). Efficient knockdown of Prkar1a in ARC POMC neurons was confirmed at study completion by double FISH detection of Pomc and Prkar1a (Fig. 5b). Successful ARC targeting was also validated by eGFP expression in ARC POMC neurons (Fig. 5b and Supplementary Fig. 7).Fig. 5ARC POMC neuron-specific Prkar1a depletion promotes intestinal glucose disposal.a, b Induction of ARC POMC neuron-specific Prkar1a depletion was achieved by injecting AAV-DIO-Prkar1a-targeting small hairpin RNA (shPrkar1a)-eGFP into the bilateral ARC in Pomc-Cre mice. Controls were injected with AAV-DIO-non-targeting shRNA (shControl)-eGFP (n = 5 male mice per group). Scale bar, 50 μm. The schematic in (a) was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. Effects of ARC POMC neuron-specific Prkar1a depletion on glucose tolerance, fecal glucose excretion (c, d, n = 5 male mice per group), intestinal Me-4FDG uptake and excretion (e, f, n = 8 for shControl; n = 6 for shPrkar1a). g Reduced jejunal SGLT1 expression in mice with ARC POMC neuron-specific Prkar1a depletion (n = 3 male mice per group). h–j Effects of ARC POMC neuron-specific PKA inhibition on semaglutide-induced glucose lowering and fecal glucose excretion. ARC POMC neuron-specific PKA inhibition was achieved via the bilateral ARC injection of AAV-DIO vectors expressing small hairpin RNAs targeting Prkaca and Prkacb (shPrkaca, shPrkacb) in Pomc-Cre male mice (n = 7 for shControl; n = 8 for shControl + Sema; n = 6 for shPrkaca/cb; n = 9 for shPrkaca/cb + Sema). The schematic in (h) was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. k Semaglutide-induced changes in intestinal SGLT1 expression in male mice with or without ARC POMC neuron–specific PKA inhibition (n = 7 for shControl; n = 6 for shControl + Sema; n = 8 for shPrkaca/cb, and shPrkaca/cb + Sema). Scale bar, 100 μm. Data are the mean ± s.e.m. Statistical analyses used were two-tailed unpaired Student’s t test (b, e, f, g, k), one-way ANOVA with Tukey’s test (c, d, i, j), and repeated measures two-way ANOVA (e, i-graph). Source data are provided as a Source data file. ARC POMC neuron-specific Prkar1a depletion promotes intestinal glucose disposal. a, b Induction of ARC POMC neuron-specific Prkar1a depletion was achieved by injecting AAV-DIO-Prkar1a-targeting small hairpin RNA (shPrkar1a)-eGFP into the bilateral ARC in Pomc-Cre mice. Controls were injected with AAV-DIO-non-targeting shRNA (shControl)-eGFP (n = 5 male mice per group). Scale bar, 50 μm. The schematic in (a) was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. Effects of ARC POMC neuron-specific Prkar1a depletion on glucose tolerance, fecal glucose excretion (c, d, n = 5 male mice per group), intestinal Me-4FDG uptake and excretion (e, f, n = 8 for shControl; n = 6 for shPrkar1a). g Reduced jejunal SGLT1 expression in mice with ARC POMC neuron-specific Prkar1a depletion (n = 3 male mice per group). h–j Effects of ARC POMC neuron-specific PKA inhibition on semaglutide-induced glucose lowering and fecal glucose excretion. ARC POMC neuron-specific PKA inhibition was achieved via the bilateral ARC injection of AAV-DIO vectors expressing small hairpin RNAs targeting Prkaca and Prkacb (shPrkaca, shPrkacb) in Pomc-Cre male mice (n = 7 for shControl; n = 8 for shControl + Sema; n = 6 for shPrkaca/cb; n = 9 for shPrkaca/cb + Sema). The schematic in (h) was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. k Semaglutide-induced changes in intestinal SGLT1 expression in male mice with or without ARC POMC neuron–specific PKA inhibition (n = 7 for shControl; n = 6 for shControl + Sema; n = 8 for shPrkaca/cb, and shPrkaca/cb + Sema). Scale bar, 100 μm. Data are the mean ± s.e.m. Statistical analyses used were two-tailed unpaired Student’s t test (b, e, f, g, k), one-way ANOVA with Tukey’s test (c, d, i, j), and repeated measures two-way ANOVA (e, i-graph). Source data are provided as a Source data file. The knockdown of Prkar1a in ARC POMC neurons significantly attenuated the rise in plasma glucose levels during the OGTT, an effect that was blunted by atropine and ATMN pretreatment (Fig. 5c). This targeted depletion also increased fecal glucose excretion following oral glucose administration, which was similarly abolished by both atropine and ATMN (Fig. 5d). Consistent with these findings, Me-4FDG absorption was decreased, and fecal excretion increased in mice injected with shPrkar1a-AAV compared to those injected with shControl-AAV (Fig. 5e, f). In addition, Prkar1a knockdown in ARC POMC neurons reduced jejunal SGLT1 expression (Fig. 5g). Collectively, these results indicated that PKA activation specifically in ARC POMC neurons enhances intestinal glucose disposal, thereby improving glucose tolerance. Body weight, cumulative food intake, and fat and lean mass did not differ between mice injected with shControl or shPrkar1a (Supplementary Fig. 8a–d). Moreover, there were no differences in insulin tolerance tests, the HOMA-IR index, skeletal muscle insulin signaling assessed by Akt phosphorylation, or histological features of adipose tissue, liver, and skeletal muscle between these shControl and shPrkar1a groups (Supplementary Fig. 8e–i). These findings indicated that the improved glucose tolerance induced by hypothalamic POMC-restricted Prkar1a knockdown is not mediated by alterations in energy balance or systemic insulin sensitivity. As semaglutide activates PKA signaling in ARC POMC neurons (Fig. 1a), we next examined whether inhibition of PKA in these neurons attenuates the glucose-lowering effects of semaglutide. To selectively inhibit PKA signaling in ARC POMC neurons, the catalytic subunits of PKA (Prkaca and Prkacb) were depleted by bilateral ARC injection of a 1:1 mixture of AAVs that express shRNAs targeting these genes in a Cre-dependent manner in Pomc-Cre mice (Fig. 5h). Two weeks after AAV injection, mice were treated with semaglutide (30 nmol/kg) or saline by daily subcutaneous injection for 5 days. Control mice received shControl-AAV and saline injections (Fig. 5h). Successful viral transduction and effective blockade of semaglutide-induced PKA activation in POMC neurons were confirmed at the end of the study (Supplementary Fig. 9a, b). Under conditions of insulin secretion blockade by somatostatin, semaglutide significantly improved glucose tolerance and increased fecal glucose excretion compared with saline-treated controls in mice injected with shControl-AAV (Fig. 5i, j). These effects were completely abolished in mice with POMC-specific PKA inhibition (Fig. 5i, j). In addition, semaglutide markedly reduced jejunal SGLT1 expression, an effect that was substantially attenuated by inhibition of PKA signaling in POMC neurons (Fig. 5k). We performed similar experiments using tirzepatide (10 nmol/kg). In contrast to semaglutide, tirzepatide improved glucose tolerance without affecting fecal glucose excretion, and inhibition of POMC PKA signaling failed to attenuate the glucose-lowering effect of tirzepatide (Supplementary Fig. 9c, d). Together, these findings indicate that semaglutide improves glucose tolerance through a POMC PKA-dependent mechanism involving enhanced intestinal glucose disposal, whereas this pathway does not appear to be critical for tirzepatide-mediated regulation of glucose tolerance. Notably, inhibition of POMC PKA signaling did not affect semaglutide- or tirzepatide-induced reduction in body weights (Supplementary Fig. 9e). The hypothalamic POMC neuron → DMV → upper gut circuit regulates intestinal glucose disposal To further explore the neuronal circuitry linking ARC POMC neurons to the upper small intestine, we conducted retrograde tracing by injecting eGFP-expressing pseudorabies virus (eGFP-PRV) into the upper jejunum (Fig. 6a). By 5 days post-injection, strong eGFP expression was observed in neuronal somata within the dorsal motor nucleus of the vagus (DMV) and their projections to the NTS (Fig. 6a-i). By day 7, eGFP signals appeared in ARC POMC neurons (Fig. 6a-ii), confirming a polysynaptic connection between ARC POMC neurons and the upper gut via the DMV. To determine whether ARC POMC neurons form direct synapses with gut-innervating DMV neurons, we performed combined anterograde and retrograde tracing. An AAV-hSyn-DIO-mCherry construct was injected into the ARC of Pomc-Cre mice, followed two weeks later by upper gut injection of PRV-eGFP, five days before sacrifice (Fig. 6b). Brainstem analysis revealed mCherry-labeled POMC axonal terminals in direct apposition to eGFP-positive DMV neurons, indicating that ARC POMC neurons form synapses with upper gut-innervating DMV neurons (Fig. 6b).Fig. 6The hypothalamic POMC neurons → DMV → upper gut circuit regulates intestinal glucose disposal.a Schematic of retrograde tracing of eGFP-expressing pseudorabies virus (PRV-eGFP) injected in the upper gut. Representative images of DVC and ARC, which were collected 5 days (i) and 7 days (ii) after the injections, respectively (n = 5 male mice per group). AP area postrema, CC central canal, DMV dorsal motor nucleus of the vagus, NTS nucleus tractus solitarius; 3 V, third cerebroventricle. Scale bar, 100 μm (i) and 50 μm (ii). The schematic was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. b Schematic and representative images of combined antegrade and retrograde tracing conducted by injecting AAV-hSyn-DIO-mCherry into the ARC and PRV-eGFP into the upper intestine of Pomc-Cre mice (n = 5 male mice per group). Scale bar, 50 μm. The schematic was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. c Comparison of c-Fos expression in the upper gut-innervating DMV neurons between Prkar1aPomcKO and Prkar1aWT mice (n = 5 male mice per group). Scale bar, 50 μm. d Activation of upper gut-innervating DMV neurons via the intra-4th ventricle injection of the melanocortin 3/4 receptor agonist MT-II (n = 5 male mice per group). Scale bar, 50 μm. Effects of chemogenetic activation of the ARC POMC → DMV circuit on DMV neuronal activity (e), OGTT (f), and fecal glucose excretion (g). AAV-DIO-hM3Dq was injected bilaterally into the ARC of Pomc-Cre mice, and 3 weeks later, deschloroclozapine (DCZ) was administered via a 4th ventricle-implanted cannula 30 min before the OGTT (n = 8 male mice per group). Scale bar, 50 μm (upper panel), 20 μm (lower panel). The schematic in (e) was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. h–j Effect of chemogenetic activation of the ARC POMC → DMV circuit on intestinal Me-4FDG uptake and excretion (n = 5 male mice per group), and on intestinal SGLT1 expression (n = 8 male mice per group). Scale bar, 50 μm. Data are the mean ± s.e.m. Statistical analyses used were two-tailed unpaired Student’s t test (c, d), repeated measures two-way ANOVA (f-graph), and one-way ANOVA with Tukey’s test (f–j). ns not significant (P > 0.05). Source data are provided as a Source data file. The hypothalamic POMC neurons → DMV → upper gut circuit regulates intestinal glucose disposal. a Schematic of retrograde tracing of eGFP-expressing pseudorabies virus (PRV-eGFP) injected in the upper gut. Representative images of DVC and ARC, which were collected 5 days (i) and 7 days (ii) after the injections, respectively (n = 5 male mice per group). AP area postrema, CC central canal, DMV dorsal motor nucleus of the vagus, NTS nucleus tractus solitarius; 3 V, third cerebroventricle. Scale bar, 100 μm (i) and 50 μm (ii). The schematic was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. b Schematic and representative images of combined antegrade and retrograde tracing conducted by injecting AAV-hSyn-DIO-mCherry into the ARC and PRV-eGFP into the upper intestine of Pomc-Cre mice (n = 5 male mice per group). Scale bar, 50 μm. The schematic was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. c Comparison of c-Fos expression in the upper gut-innervating DMV neurons between Prkar1aPomcKO and Prkar1aWT mice (n = 5 male mice per group). Scale bar, 50 μm. d Activation of upper gut-innervating DMV neurons via the intra-4th ventricle injection of the melanocortin 3/4 receptor agonist MT-II (n = 5 male mice per group). Scale bar, 50 μm. Effects of chemogenetic activation of the ARC POMC → DMV circuit on DMV neuronal activity (e), OGTT (f), and fecal glucose excretion (g). AAV-DIO-hM3Dq was injected bilaterally into the ARC of Pomc-Cre mice, and 3 weeks later, deschloroclozapine (DCZ) was administered via a 4th ventricle-implanted cannula 30 min before the OGTT (n = 8 male mice per group). Scale bar, 50 μm (upper panel), 20 μm (lower panel). The schematic in (e) was created in BioRender. Kim, M.-S. (2026) https://BioRender.com/ept89e1. h–j Effect of chemogenetic activation of the ARC POMC → DMV circuit on intestinal Me-4FDG uptake and excretion (n = 5 male mice per group), and on intestinal SGLT1 expression (n = 8 male mice per group). Scale bar, 50 μm. Data are the mean ± s.e.m. Statistical analyses used were two-tailed unpaired Student’s t test (c, d), repeated measures two-way ANOVA (f-graph), and one-way ANOVA with Tukey’s test (f–j). ns not significant (P > 0.05). Source data are provided as a Source data file. We then assessed whether upper gut-innervating DMV neurons are activated in Prkar1aPomcKO mice. For this, we injected PRV-eGFP into the upper gut and collected brain tissue five days later for c-Fos and GFP double immunostaining in the brainstem. A significantly higher number of c-Fos+ GFP+ DMV neurons was observed in Prkar1aPomcKO mice compared to Prkar1aWT controls (Fig. 6c), indicating increased activity of gut-innervating DMV neurons in response to PKA activation in POMC neurons. To investigate how PKA activation in POMC neurons enhances DMV neuronal activity, we performed hypothalamic explant experiments. Chemical activation of PKA using 8-bromo-cAMP significantly increased the secretion of α-melanocyte-stimulating hormone (α-MSH) from hypothalamic explants (Supplementary Fig. 10). Furthermore, administration of the melanocortin 3/4 receptor agonist melanotan II (MT-II) into the fourth ventricle, near the DMV, elevated c-Fos expression in gut-innervating DMV neurons (Fig. 6d). Previous single-cell RNA sequencing of the dorsal vagal complex has shown Mc4r expression in DMV neurons35, and we confirmed Mc4r expression in gut-innervating DMV neurons (Supplementary Fig. 11). These findings suggested that PKA activation in ARC POMC neurons promotes α-MSH release, which in turn activates gut-innervating DMV neurons via MC4R signaling. We further investigated the impact of PKA activation in POMC neurons. Prkar1aPomcKO mice exhibited increased POMC neuronal activity, as assessed by c-Fos expression, without altering POMC neuron numbers or Pomc expression (Supplementary Fig. 12a–c). Whole-cell patch-clamp recordings of ARC POMC neurons revealed that a greater proportion of POMC neurons displayed spontaneous firing in Prkar1aPomcKO mice, with a significant increase in the spontaneous firing frequency (Supplementary Fig. 12d, e). Upon depolarizing current injections, Prkar1a-deficient POMC neurons generated more action potentials and exhibited a reduced rheobase, indicating enhanced intrinsic excitability (Supplementary Fig. 12f–h). In contrast, passive membrane properties, including resting membrane potential, input resistance, and action potential threshold, were not altered (Supplementary Fig. 12i–k). Collectively, these findings indicated that PKA activation induced by Prkar1a deletion enhances the activity and intrinsic excitability of ARC POMC neurons without affecting neuronal identity, survival, or basic membrane properties. We finally examined whether activation of the ARC POMC → DMV circuit influences gut glucose disposal. To this end, we injected AAV-DIO-hM3Dq into the ARC of Pomc-Cre mice. To selectively activate the brainstem POMC circuit, deschloroclozapine (DCZ) was administered into the 4th ventricle 30 min before the OGTT, three weeks after virus injection (Fig. 6e). Successful targeting and expression of AAV in ARC POMC neurons were confirmed by mCherry fluorescence (Fig. 6e). Chemogenetic activation of the ARC POMC → DMV circuit significantly increased DMV neuronal activity (Fig. 6e) and led to improved glucose tolerance accompanied by increased intestinal glucose excretion during OGTT (Fig. 6f, g). To further investigate the intestinal mechanisms underlying this effect, we performed Me-4FDG studies and intestinal SGLT1 immunostaining. Chemogenetic activation of the ARC POMC → DMV circuit reduced intestinal Me-4FDG uptake, increased fecal Me-4FDG excretion, and decreased intestinal SGLT1 expression (Fig. 6h–j). Importantly, this manipulation did not affect systemic insulin sensitivity, as neither insulin tolerance nor HOMA-IR was significantly altered (Supplementary Fig. 13a, b). These findings support a key role for activation of the ARC POMC → DMV circuit in the postprandial state in limiting intestinal glucose absorption and thereby mitigating postprandial hyperglycemia. Discussion The role of PKA signaling in the hypothalamic neurons has previously been studied using a mouse model with a PKA RIIβ deletion, which leads to PKA inhibition36,37, in contrast to an R1α deletion. Mice with an RIIβ deletion are lean and exhibit increased sensitivity to leptin, with this metabolic phenotype being partially mediated by PKA inhibition in neuropeptide Y (NPY)/Agouti-related peptide (AgRP) neurons37. In our current study, we have demonstrated that PKA signaling in POMC neurons plays a role in glucose regulation by regulating intestinal glucose disposal without affecting systemic insulin sensitivity, food intake, and adiposity. Moreover, this pathway is modulated by physiological factors, such as the fasting-feeding cycle, as well as by pharmacological agents, including GLP-1/GIP receptor agonists. Notably, ARC POMC PKA signaling mediates the glucose-lowering effect of the GLP-1 receptor agonist semaglutide. Although the obesity phenotype observed in our mouse model of POMC PKA activation contrasts with the weight-reducing effects of semaglutide, this phenotype is likely attributable to off-target effects on pituitary corticotrophs, resulting in corticosteroid hypersecretion. In support of this interpretation, selective activation of PKA signaling in ARC POMC neurons did not produce significant changes in body weight or fat mass. Notably, enhanced intestinal glucose disposal in Prkar1aPomcKO mice proved highly effective in lowering postprandial blood glucose levels, even in the presence of obesity, insulin resistance, hypercortisolism, and increased renal glucose reabsorption. This effect was found to be mediated, at least in part, by the regulation of intestinal SGLT1 expression. The rapid alteration of glucose tolerance following pharmacological manipulation of parasympathetic signaling is unlikely to reflect de novo transcriptional or translational regulation of SGLT1. Indeed, SGLT1 activity and membrane localization can be rapidly modulated (within minutes) by post-translational mechanisms in response to neural or hormonal inputs38. This rapid regulation aligns with our observation that either atropine or acetylcholine administration alters intestinal glucose uptake within 30 min. These findings support the previously reported therapeutic potential of SGLT1-targeting antidiabetic drugs in individuals with obesity and insulin resistance39. In line with this, both selective SGLT1 inhibitors and dual SGLT1/SGLT2 inhibitors are currently undergoing clinical trials to assess their efficacy in improving hyperglycemia in patients with diabetes mellitus40,41. SGLT1 inhibition has been shown to enhance GLP-1 release by reducing glucose absorption in the upper gut and increasing glucose delivery to the distal gut42. In contrast, reduced SGLT1 expression may impair GLP-1 secretion in response to luminal glucose by disrupting glucose sensing43. In our current study, Prkar1aPomcKO mice exhibited no significant changes in plasma GLP-1 concentrations during an OGTT, suggesting that GLP-1 plays a minimal role in the altered gut glucose phenotype observed in these animals. Our study also revealed a neural circuit linking hypothalamic POMC neurons to the upper gut via the DMV–vagal pathway. POMC expression in hypothalamic neurons is known to regulate renal glucose reabsorption through the sympathetic nervous system28. In contrast, and consistent with our current findings, previous studies have shown that hypothalamic POMC neurons regulate glucose-stimulated insulin secretion by modulating parasympathetic innervation of the pancreatic islets44. That same study also suggested that the connection between POMC neurons and the parasympathetic nervous system may be mediated by preautonomic neurons in the hypothalamic paraventricular nucleus44. In our present investigation, direct innervation of gut-innervating DMV neurons by ARC POMC neurons was demonstrated. Furthermore, chemogenetic activation of this pathway was found to improve glucose tolerance by enhancing gut glucose disposal. Collectively, these findings define a mechanism through which ARC POMC neurons regulate glucose homeostasis via the DMV–vagal–gut axis. Finally, our findings suggest a potential mechanism for the POMC PKA-mediated regulation of intestinal glucose disposal. Treatment with a chemical PKA activator stimulated α-MSH secretion from hypothalamic explants, potentially in association with the increased neuronal activity of POMC neurons. Furthermore, administration of the MC4R agonist into the fourth ventricle activated DMV neurons that project to the upper gut. Given that ARC POMC neurons send axonal projections to DMV neurons, the increased α-MSH secretion at POMC–DMV synapses in Prkar1aPomcKO mice may activate DMV neurons via MC4R. Although we did not directly investigate how DMV neuron activation leads to decreased intestinal SGLT1 expression and reduced glucose absorption, previous studies have shown that the vagal pathway plays a role in both the circadian regulation of gut SGLT1 expression and the dietary modulation of intestinal glucose absorption45–47. In summary, our study highlights the importance of POMC PKA signaling in a brain–gut circuit that regulates intestinal glucose disposal and reveals its therapeutic potential for managing postprandial hyperglycemia independently of insulin. Methods Mouse models and husbandry To generate POMC neuron-specific Prkar1a-deficient mice, Pomc–Cre mice (Obtained from Joel K. Elmquist, University of Texas Southwestern Medical Center) were crossed with Prkar1afl/fl mice (Jackson laboratory #036801). To induce maturity-onset POMC-specific Prkar1a depletion, Pomc-CreERT2 mice (Obtained from Joel K. Elmquist) were crossed with Prkar1afl/fl mice. Gene knockdown was induced by the intraperitoneal injection of tamoxifen (75 mg/kg) for 5 consecutive days. Prkar1afl/fl mice served as wild-type controls and received the same tamoxifen treatment. C57BL/6J mice aged 7−8 weeks were obtained from Orient Bio (Seongnam, Korea). All mice had free access to a standard chow diet (containing 12.5% of calories from fat; Cargill Agri Purina, 38057) and water, unless otherwise specified. Animals were housed in specific pathogen-free (SPF) rooms under controlled temperature (22 ± 1 °C) and humidity (50 ± 10%), with a 12 h light-dark cycle (lights on at 8 AM). All animal procedures were approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Science (#2019−13−250). Body weight and lean and fat mass measurements Body weights were monitored weekly during the early light period. Body composition parameters, including lean mass and fat mass, were measured at specified ages using dual-energy X-ray absorptiometry (iNSiGHT VET DXA, OsteoSys, Seoul, Korea). Glucose and insulin tolerance test In the oral glucose tolerance test, D-glucose (1 g/kg, Sigma) was administered via oral gavage in overnight fasted mice. In the insulin tolerance test, overnight fasted mice were injected with insulin (Humulin-R 0.25 mU/kg; Eli Lilly, Indianapolis, IN) via the peritoneal cavity. Blood was obtained from tail veins for glucose measurements immediately before, and 15, 30, 60, 90, and 120 min after glucose and insulin injections. Glucose levels were measured using a glucometer (ACCU-CHEK, Aviva Plus System, London, UK). To block the sympathetic and parasympathetic nervous system, phentolamine (15 mg/kg, Sigma‑Aldrich, St. Louis, MO), propranolol (10 mg/kg, Sigma‑Aldrich), atropine (1 mg/kg; 0.1 g/ml dissolved in methanol and diluted 1:1000 in saline, Sigma‑Aldrich) or ATMN (2 mg/kg; 25 mg/ml dissolved in ethanol and diluted 1:125 in saline, Cayman Chemical, Ann Arbor, MI) were administered intraperitoneally 30 min before the OGTT. To stimulate the parasympathetic nervous system, acetylcholine (25 mg/kg, Sigma-Aldrich) was administered intraperitoneally 30 min before the OGTT. To block SGLT1, phlorizine (2 mg, Sigma‑Aldrich) was dissolved in 1 mL of 20% propylene glycol-water (v/v) and administered at a volume of 5 μL per gram of body weight 30 min before the assay. For intravenous glucose tolerance testing (IVGTT), a venous catheter (PE50) was surgically implanted into the right jugular vein, tunneled under the skin, and exteriorized above the neck under anesthesia with Zoletil® (40 mg/kg) and Rompun® (5 mg/kg). After a 3-day recovery period, overnight fasted mice received a bolus injection of glucose (1 g/kg). Blood samples were collected from the tail veins at 15, 30, 60, 90, and 120 min for glucose measurement. Fecal and urine glucose excretion Feces and urine were collected for indicated periods, weighed, and stored at −70 °C until assay. The feces were thawed and homogenized in 300 μL PBS. After centrifugation (2000 × g for 20 min and then 1000 × g for 10 min), the supernatant was collected to measure glucose levels using a glucose analyzer (Analox Instruments, Stourbridge, UK). Me-4FDG uptake and excretion Following an overnight fast, mice received an oral gavage of 300 μCi Me-4FDG dissolved in drinking water. Blood fluorine-18 activity was then measured at baseline (0 min) and 15, 30, 60, and 120 min post-administration. A blood sample (1 μL) was collected from the tail vein using a glucose meter strip, and the strips were analyzed for fluorine-18 activity using Wizard2 Gamma Counter (PerkinElmer, Waltham, MA). Feces were collected for 2 h after Me-4FDG injection, and fluorine-18 activity in the feces collected each hour was measured using a gamma counter. Bilateral adrenalectomy Mice were anesthetized with Zoletil® (40 mg/kg) and Rompun® (5 mg/kg). A 2 × 2 cm area on the lower dorsal surface was shaved, and an incision was made along the dorsal midline to access and remove both adrenal glands. A small incision (3–5 mm) was made in the muscle layer above the kidney, allowing careful extraction of the adrenal gland using tweezers. The same procedure was performed on the opposite side to complete the bilateral adrenalectomy. After the procedure, the muscle incisions were sutured, and the dorsal skin was closed with wound clips. Corticosterone replacement was provided through the animals’ drinking water, available ad libitum. Corticosterone (10 μg/mL) was first dissolved in a small amount of ethanol (0.6%) before being mixed with distilled water. Since adrenalectomy removes the aldosterone-producing cells of the adrenal gland, NaCl (0.9%) was added to compensate for salt loss. Additionally, sucrose (2.0%) was included to enhance the palatability of the solution. shRNA study To induce ARC POMC-specific Prkar1a depletion, either an AAV-EF1a-DIO-TATAlox-DSE-EGFP-shPrkar1a or AAV-EF1a-DIO-TATAlox-DSE-EGFP-shControl (1 × 1013 GC/mL, 0.5 μL) construct (both from Virus Core of the Korean Institute for Science and Technology) was bilaterally injected (2 sites per side) into the ARC of Pomc-Cre mice. The injection coordinates were 0.2 mm from the midline, at −1.4 (anterior ARC) and −1.7 mm (posterior ARC) relative to the bregma, and −5.75 mm from the skull surface. Mice underwent an OGTT and a fecal glucose excretion study. At the end of the study period, Me-4FDG uptake and excretion were assessed. Brain tissues were collected to confirm the successful depletion of Prkar1a in ARC POMC neurons and to verify the correct viral targeting of the ARC. To study whether PKA activation in POMC neurons may mediate the glucose-lowering effect of semaglutide and tirzepatide, we inhibited PKA inhibition in ARC POMC neurons by injecting a 1:1 mixture of AAV/DJ-EF1a-DIO-TATAlox-DSE-EGFP-shPrkaca and AAV-EF1a-DIO-TATAlox-DSE-EGFP-shPrkacb. Control mice received shControl-AAV injections. Two weeks after AAV injection, the mice were treated with either semaglutide (30 nmol/kg), tirzepatide (10 nmol/kg), or saline via a daily intraperitoneal injection at 5:00 PM for 5 days with daily monitoring of body weights. On the morning of the sixth day, mice were subjected to an OGTT following an overnight fast. Somatostatin (100 μg/kg) was administered intraperitoneally 10 min before the OGTT to block semaglutide- or tirzepatide-induced insulin secretion. Feces were collected after the OGTT to measure fecal glucose excretion. At the end of the study, the brain and jejunum were collected from mice under overnight-fasted conditions, 30 min after injection of saline, semaglutide, or tirzepatide, and 40 min after injection of somatostatin. Successful inhibition of PKA activity in POMC neurons was confirmed by POMC and pCREB double immunohistochemistry at the end of the study (Supplementary Fig. 9b). Antegrade and retrograde virus tracing The upper jejunum was surgically exposed under anesthesia. Pseudorabies virus (PRV152) expressing eGFP (eGFP-PRV; 4.45 × 10⁸ pfu/ml) (from Virus Core of Princeton University) was injected into four sites of the upper jejunum, with a volume of 0.5 μL per site. At 5 and 7 days post-injection, the mice underwent cardiac perfusion for brain tissue harvesting. Brain slices encompassing the hypothalamus and brainstem were prepared using a cryostat (Leica, Wetzlar, Germany) to examine eGFP-expressing neurons. In the combined antegrade and retrograde tracing study, AAV8-hSyn-DIO-mCherry (Addgene) was injected into the ARC of Pomc-Cre mice as previously described48. Five days after the AAV injection, the mice received eGFP-PRV injections to the upper jejunum. The animals were sacrificed at 5 days after PRV intrajejunal injection, and the brains were collected for confocal microscopy analysis. Fourth ventricle cannulation and injection Under anesthesia, 27-gauge stainless steel cannulas were implanted using stereotaxic surgery at a 10° angle, with coordinates anteroposterior −6.8 mm (posterior to bregma), lateral −0.8 mm, and dorsoventral −4.3 mm below the skull surface, leveled between the lambda and bregma. Seven days after surgery, melanotan-II (MT-II, 10 nmol/2 μL, Phoenix Pharmaceuticals, Burlingame, CA) was administered through the cannula 30 min prior to sacrifice. Chemogenetic activation of POMC → DMV circuits To selectively target DMV POMC neurons, Pomc-Cre mice (10–12 weeks old) were bilaterally injected in the ARC of the hypothalamus with either rAAV-hSyn-DIO-hM3Dq-mCherry (from Virus Core of the Korean Institute for Science and Technology) or AAV5-hSyn-DIO-mCherry (from Addgene) using stereotaxic surgery. Under anesthesia, a total of 2 μL of viral solution was injected, divided equally between two anteroposterior sites (−1.45 mm and −1.75 mm) relative to the bregma, using the coordinates lateral −0.2 mm and dorsoventral −5.8 mm. To enable activation of hM3Dq-expressing neurons in the DMV, a 27-gauge stainless steel cannula was stereotaxically implanted into the 4th ventricle 2 weeks after viral injection (coordinates: AP −7.5 mm, ML −1.76 mm, DV −3.82 mm from the bregma, at a 15° angle). After 2 weeks, on the day of the experiment, deschloroclozapine (DCZ, 0.3 mg/kg in sterile saline) was injected through the cannula. DCZ was delivered in a volume of 2 µL over 2 min, and the injector was left in place for an additional 1 min to ensure diffusion. Mice were sacrificed at 30 min after DCZ administration for downstream analysis. Histological analysis and immunostaining Various mouse organs were dissected, weighed, and fixed in 4% paraformaldehyde (PFA) overnight, then rinsed with distilled water. The tissues were paraffin-embedded, sectioned at a 5 μm thickness, and subjected to hematoxylin-eosin (H & E) staining. For the immunostaining of brain tissues, anesthetized mice were transcardially perfused with 4% PFA in 0.1 M phosphate buffer (pH 7.4), and brains were collected. The brains were incubated overnight at 4 °C, then transferred to a 30% sucrose solution for 2 days. Thirty-micrometer (30 μm) brain sections were collected at every third interval, resulting in 12–14 slices per slide. Slides were blocked in 3% bovine serum albumin (BSA) and 0.5% Triton X-100 in PBS (PBST) for 1 h at room temperature (RT). For double immunostaining of POMC and phosphorylated CREB (pCREB), tissue sections were first incubated with a primary antibody against β-endorphin (1:500; rabbit; #H-022-33, Phoenix Pharmaceuticals) in blocking solution for 24 h at RT. After incubation, sections were treated with Alexa Fluor-conjugated secondary antibodies (1:500) for 1 h at RT. Prior to mounting, sections were incubated with DAPI (1:10,000) for 10 min and TrueBlack (diluted 1:25 in 70% ethanol) for 5 min at RT. After acquisition of confocal images, β-endorphin staining was stripped by serial incubation of VRX-1000 A and B regents (Vector Laboratories, Newark, CA), followed by PBS washes. Sections were then blocked with 3% donkey serum and 0.1% PBST and incubated with an antibody against pCREB (1:500; rabbit; #9198, Cell Signaling Technology, Danvers, MA) for 24 h at RT. For c-Fos immunostaining, sections were blocked in 10% goat serum and 0.5% PBST for 1 h at RT. The c-Fos primary antibody (1:500, rabbit, #226003, Synaptic Systems, Goettingen, Germany) was incubated in blocking solution for 24 h at 4 °C, followed by incubation with the secondary antibody (Alexa Fluor 633-goat anti-rabbit IgG, 1:1000) in PBS for 1 h at RT. In each slice, the numbers of POMC-positive and c-Fos-positive cells were counted, and the proportion of POMC neurons co-expressing c-Fos was calculated as a percentage. For intestinal SGLT1 immunostaining, a 7 cm segment of upper jejunum was isolated from each animal and divided into seven 1 cm pieces. The luminal surfaces were opened and used for staining and quantification. Heat-mediated antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0), followed by blocking with 10% goat serum for 1 h at RT. The SGLT1 primary antibody (1:800, rabbit, #30861-1-AP, Proteintech, Rosemont, IL) was incubated in 3% BSA and 0.5% PBST for 2 h at RT, followed by incubation with the secondary antibody (Alexa Fluor 633-goat anti-rabbit IgG, 1:1000) in PBS for 1 h at RT. Thus, seven sections per animal were analyzed, and all quantifications were performed in a blinded manner. Immunofluorescence staining for insulin was performed on paraffin-embedded pancreatic tissue sections. After deparaffinization, endogenous peroxidase activity was blocked by incubation with 0.5% hydrogen peroxide in methanol for 10 min. Heat-induced antigen retrieval was carried out in 10 mM sodium citrate buffer (pH 6.0) for 5 min, followed by cooling on ice for 15 min. Sections were permeabilized in 0.5% PBST for 5 min and blocked with 3% donkey serum in PBS for 1 h at RT. The tissues were incubated overnight at 4 °C with a primary antibody against insulin (1:500, rabbit, #sc-9168, Santa Cruz Biotechnology, Dallas, TX) diluted in blocking solution. After thorough washing, sections were incubated with secondary antibody (Alexa Fluor 488-conjugated goat anti-rabbit IgG, 1:500) in PBS for 1 h at RT. To evaluate skeletal muscle lipid accumulation, quadriceps muscles were collected without transcardial perfusion, embedded in OCT compound, and snap-frozen. Cryosections (20 μm thickness) were prepared and blocked with 10% goat serum in PBS for 1 h at RT. Sections were incubated with an anti-laminin antibody (1:500, rabbit, #L9393, Sigma-Aldrich) diluted in blocking solution for 2 h at RT, followed by incubation with an Alexa Fluor 555-conjugated goat anti-rabbit IgG secondary antibody for 1 h at RT. Neutral lipid droplets were visualized by incubation with BODIPY 493/503 (1:1000, #D3922, Invitrogen, Carlsbad, CA) for 10 min at RT. Sections were then mounted for imaging. Imaging was performed using confocal microscopy (Carl Zeiss, Oberkochen, Germany). Fluorescent in situ hybridization Mice were perfused with 4% PFA solution dissolved in DEPC water through the left ventricle. Whole brains and the upper jejunum were collected, post-fixed overnight, and then dehydrated in a 30% sucrose solution for 48 h. The brains were then sectioned at a 14-μm thickness using a cryostat. Fluorescence in situ hybridization (FISH) was then performed using RNAscope® fluorescent multiplex reagents provided by Advanced Cell Diagnostics (Newark, CA). RNA probes specific to mouse Prkar1a or Pomc (Advanced Cell Diagnostics) were applied to the tissue slices, and signal amplification was achieved using multiplex reagents. For double FISH and IF staining involving Prkar1a and β-endorphin, the brain slices underwent Prkar1a FISH and then β-endorphin immunostaining. Measurement of PKA activity The mediobasal hypothalamus, dorsal vagal complex, and pituitary tissues were bilaterally collected via a punch biopsy using a 26-gauge needle, snap-frozen in liquid nitrogen, and stored at −70 °C. The terminal ileum was also collected from the experimental mice, finely minced with scissors, and homogenized prior to the assay. PKA activity was measured using a PKA colorimetric activity kit (Invitrogen). In the assay, tissues were homogenized in 1 mL of 1× kinase buffer. After centrifugation (1000 × rpm, 10 min), 40 μL of the supernatant was used for the assay. ELISA Plasma insulin and GLP-1 levels were measured using ELISA (Insulin, ALPCO Diagnostics, Salem, NH; GLP-1, Millipore, Burlington, MA). Plasma corticosterone levels were analyzed using a commercial ELISA kit (Cayman Chemical). Immunoblotting To isolate proteins from the small intestinal mucosa, the mucosal surface was scraped using the blunt side of a scalpel blade, and the collected tissue was stored at −70 °C until use. Equal amounts of protein (50 µg per sample) were resolved on 8% SDS-PAGE gels and transferred onto PVDF membranes. For immunoblotting, membranes were blocked with 5% BSA in 0.1% Tris Buffered Saline with Tween-20 (TBST, 20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at RT and then incubated overnight at 4 °C with a primary antibody against SGLT1 (1:1000, rabbit, #30861-1-AP, Proteintech) diluted in the same blocking solution. For detection of β-actin (1:1000, #sc-47778, Santa Cruz), membranes were cut based on size markers and separately blocked with 5% skim milk in 0.1% TBST for 2 h at RT. For the detection of phosphorylated and total Akt, membranes were blocked with 3% BSA in 0.1% PBST for 1 h at RT and incubated overnight at 4 °C with antibodies against phospho-Akt (Ser473; 1:1000, #9271, Cell Signaling Technology) or total Akt (1:1000, #9272, Cell Signaling Technology) diluted in 3% BSA in 0.1% PBST. After washing, membranes were incubated with HRP-conjugated secondary antibodies (1:1000), and protein bands were visualized using a chemiluminescence detection system. Hypothalamic explant experiments Hypothalamic explant experiments were conducted using acute brain slices. Brains from C57BL6 mouse were rapidly removed following decapitation and placed in high-sucrose ice-cold oxygenated artificial cerebrospinal fluid (ACSF) containing the following (in mM): 180 sucrose, 2.5 KCl, 1.2 NaH2PO4, 25 NaHCO3, 25 D-glucose, 10 MgSO4, and 0.5 CaCl2, pH 7.3, and 95% O2/5% CO2. Coronal brain slices were cut at a thickness of 250 µm using a vibratome (VT1200S; Leica Biosystems, Nussloch, Germany) and immediately transferred to an incubation chamber filled with modified ACSF containing the following (in mM): 124 NaCl, 2.5 KCl, 1.2 NaH2PO4, 24 NaHCO3, 5 HEPES, 12.5 glucose, 4 MgSO4, and 2 CaCl2 (pH 7.3), equilibrated with 95% O2 and 5% CO2. Slices were allowed to recover at 35 °C for 30 min. Following recovery, the ARC was dissected from the brain slices and transferred into a 6-well plate containing standard ACSF containing the following (in mM): 124 NaCl, 2.5 KCl, 1.2 NaH2PO4, 24 NaHCO3, 5 HEPES, 12.5 glucose, 1 MgSO4, and 2 CaCl2 (pH 7.3), equilibrated with 95% O2 and 5% CO2. The ARC sections were incubated with various concentrations of 8-bromo-cAMP (MedChem Express, Monmouth Junction, NJ) for an hour at 37 °C, before the ACSF was collected and snap-frozen in liquid nitrogen. The α-MSH levels in the supernatants were then measured using a commercial ELISA kit (LSBio, Seattle, WA). Gene expression Kidney and mediobasal hypothalamic blocks were harvested, snap frozen in liquid nitrogen, and stored at –70 °C. Total RNA was subsequently extracted from these tissues using TRIzol in accordance with the manufacturer’s protocol. Five microgram RNA aliquots were then reverse transcribed to generate cDNA. The threshold cycle (CT) values were normalized to that of glyceraldehyde 3-phosphate dehydrogenase (Gapdh). The primers used for qPCR analysis are listed in Supplementary Table 1. Whole-cell patch clamp recording To label ARC POMC neurons, Pomc-Cre or Prkar1aPomcKO mice received bilateral injections of hSyn-DIO-mCherry-AAV5 (Addgene, Watertown, MA) into the ARC. Two weeks later, acute brain slices were prepared as previously described49. Whole-cell patch-clamp recordings were performed on the mCherry-expressing ARC neurons, visualized using the pE-800 fluorescence illumination system (CoolLED, Andover, UK), IRIS 9 sCMOS camera (Teledyne Photometrics, Tucson, AZ), and monitor. Pipettes used for recordings were pulled from borosilicate glass capillaries with a filament (length 100 mm, outer diameter 1.5 mm, inner diameter 0.84 mm; 1B150F-4, WPI) with the P-1000 micropipette puller (Sutter Instrument, Novato, CA). Patch pipettes (5–7 MΩ) were filled with an internal solution containing (in mM) 130 K-gluconate, 5 NaCl, 11 KCl, 1 MgCl2, 10 HEPES, 0.1 EGTA, 2 Mg-ATP, 0.3 Na-GTP, and 5 Na2-phosphocreatine (pH 7.3 with KOH; 295 mOsm) for recording. Access resistance, membrane resistance, and membrane capacitance were monitored during the experiment to ensure the stability and health of the cells. Action potentials are evoked by the injection of depolarizing current pulses in current-clamp mode. Recordings were performed with pCLAMP11 (Molecular Devices, San Jose, CA). Data were analyzed using AxoGraph Version 1.8.0 (AxoGraph, Union City, CA). Statistical analysis Statistical analyses were performed using Prism software version 9.0 (GraphPad, San Diego, CA) or SPSS version 24 (IBM Analytics, Armonk, NY). Two-tailed unpaired Student’s t tests were used to compare two independent groups; one-way ANOVA followed by Tukey’s post-hoc analysis was used to compare three or more groups; repeated-measures ANOVA was used when the same subjects were measured across multiple time points or conditions. Statistical significance was defined at P < 0.05. The data are presented as a mean ± standard error of the mean (s.e.m.). Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary Information Reporting Summary Transparent Peer Review File Supplementary Information Reporting Summary Transparent Peer Review File Source data Source Data Source Data